Koss Olinger Consulting, LLC Intellia Therapeutics, Inc. Transaction History
Koss Olinger Consulting, LLC
- $1.2 Billion
- Q2 2025
A detailed history of Koss Olinger Consulting, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Koss Olinger Consulting, LLC holds 10,000 shares of NTLA stock, worth $114,600. This represents 0.01% of its overall portfolio holdings.
Number of Shares
10,000Holding current value
$114,600% of portfolio
0.01%Shares
3 transactions
Others Institutions Holding NTLA
# of Institutions
344Shares Held
98.6MCall Options Held
784KPut Options Held
713K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl13MShares$149 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.8MShares$123 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$110 Million0.0% of portfolio
-
State Street Corp Boston, MA4.51MShares$51.7 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.8MShares$43.6 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $871M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...